TrialBlood advances2021
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Nobuko Hijiya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled ittrialcites it